SUNHAWKVISION BIOTECH (7759) announced the expansion of its core technology platform by officially filing a patent application with the United States Patent and Trademark Office (USPTO), specifically targeting ocular toxicities and complications induced by Antibody-Drug Conjugates (ADCs).

While the global ADC oncology market commands tens of billions of dollars, ocular toxicity has emerged as a dose-limiting vulnerability for international pharmaceutical giants. Approved ADC therapeutics, such as Elahere, report ocular adverse events and ocular surface disorders in up to 50% to 56% of patients. Most notably, the former blockbuster ADC Blenrep was requested by the FDA to be withdrawn from the market, largely driven by severe ocular toxicities and an alarming 83% dose modification rate.

Currently, there are no approved therapies worldwide specifically indicated for the prevention or treatment of ADC-induced ocular toxicity. Powered by robust, clinically proven efficacy in ocular tissue repair, SUNHAWKVISION pioneers this vast, unaddressed blue ocean—firmly securing the commanding strategic high ground in the multi-billion-dollar oncology supportive care market.